Predictive Factors for Switched EGFR-TKI Retreatment in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

BACKGROUND: Third-generation tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) have proved efficacious in treating non-small cell lung cancer (NSCLC) patients with acquired resistance resulting from the T790M mutation. However, since almost 50% patients with the acquired...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Tuberc Respir Dis (Seoul)
Autors principals: Kwon, Byoung Soo, Park, Ji Hyun, Kim, Woo Sung, Song, Joon Seon, Choi, Chang-Min, Rho, Jin Kyung, Lee, Jae Cheol
Format: Artigo
Idioma:Inglês
Publicat: The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5392490/
https://ncbi.nlm.nih.gov/pubmed/28416959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4046/trd.2017.80.2.187
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars